Subscribe
Area Development Magazine Current Issue
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

Bio Pharma R&D Stays Strong Despite Economics

05/04/2010
Biopharmaceutical research companies haven't let the recession impede research and development and invested a record $65.3 billion last year in the research and development of new life-changing medicines and vaccines-an increase of more than $1.5 billion from 2008, according to analyses by the Pharmaceutical Research and Manufacturers of America (PhRMA) and Burrill & Company .

PhRMA-member companies alone spent an estimated $45.8 billion on pharmaceutical R&D last year, according to the survey. The Burrill & Company analysis shows that non-PhRMA pharmaceutical research companies in the United States spent an estimated $19.5 billion on R&D in 2009.

While companies have been forced to make difficult business decisions, research spending as a percentage of sales remained high in 2009. Over the past nine years, America's pharmaceutical research companies have consistently invested around 18 percent of domestic sales on R&D activities.

"America's biopharmaceutical research sector takes great pride in its global leadership in the development of new life-saving treatments and cures," said PhRMA President and CEO Billy Tauzin.

Magazine

Past Issues
Area Development Magazine Q1 2026
Q1 2026

Receive quarterly issues of Area Development Magazine at no charge for qualified executives and consultants to industry.

Exclusive Research